X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs TORRENT PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD TORRENT PHARMA BIOCON LTD/
TORRENT PHARMA
 
P/E (TTM) x 49.9 44.1 113.2% View Chart
P/BV x 7.3 6.0 121.4% View Chart
Dividend Yield % 0.2 0.9 18.6%  

Financials

 BIOCON LTD   TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
TORRENT PHARMA
Mar-18
BIOCON LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1881,550 76.6%   
Low Rs3051,144 26.7%   
Sales per share (Unadj.) Rs68.7354.7 19.4%  
Earnings per share (Unadj.) Rs7.640.1 18.8%  
Cash flow per share (Unadj.) Rs14.064.2 21.8%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.11.0 12.9%  
Book value per share (Unadj.) Rs86.3273.1 31.6%  
Shares outstanding (eoy) m600.00169.22 354.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.8 286.1%   
Avg P/E ratio x98.933.6 294.1%  
P/CF ratio (eoy) x53.421.0 254.8%  
Price / Book Value ratio x8.64.9 175.3%  
Dividend payout %13.234.9 37.9%   
Avg Mkt Cap Rs m447,900227,897 196.5%   
No. of employees `0006.114.7 41.8%   
Total wages/salary Rs m9,31111,353 82.0%   
Avg. sales/employee Rs Th6,705.84,083.0 164.2%   
Avg. wages/employee Rs Th1,514.2772.3 196.1%   
Avg. net profit/employee Rs Th736.9461.3 159.7%   
INCOME DATA
Net Sales Rs m41,23460,021 68.7%  
Other income Rs m2,0622,988 69.0%   
Total revenues Rs m43,29663,009 68.7%   
Gross profit Rs m8,29113,493 61.4%  
Depreciation Rs m3,8514,086 94.2%   
Interest Rs m6153,085 19.9%   
Profit before tax Rs m5,8879,310 63.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,529 62.0%   
Profit after tax Rs m4,5316,781 66.8%  
Gross profit margin %20.122.5 89.4%  
Effective tax rate %26.727.2 98.1%   
Net profit margin %11.011.3 97.3%  
BALANCE SHEET DATA
Current assets Rs m41,48652,623 78.8%   
Current liabilities Rs m21,41352,022 41.2%   
Net working cap to sales %48.71.0 4,857.6%  
Current ratio x1.91.0 191.5%  
Inventory Days Days64120 53.5%  
Debtors Days Days9476 123.5%  
Net fixed assets Rs m50,66185,016 59.6%   
Share capital Rs m3,000846 354.5%   
"Free" reserves Rs m48,80845,376 107.6%   
Net worth Rs m51,80846,222 112.1%   
Long term debt Rs m17,89841,115 43.5%   
Total assets Rs m99,897142,432 70.1%  
Interest coverage x10.64.0 263.1%   
Debt to equity ratio x0.30.9 38.8%  
Sales to assets ratio x0.40.4 98.0%   
Return on assets %5.26.9 74.4%  
Return on equity %8.714.7 59.6%  
Return on capital %9.614.2 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05814,580 82.7%   
Fx outflow Rs m7,3483,600 204.1%   
Net fx Rs m4,71010,980 42.9%   
CASH FLOW
From Operations Rs m6,6218,942 74.0%  
From Investments Rs m-6,840-47,070 14.5%  
From Financial Activity Rs m-2,39734,174 -7.0%  
Net Cashflow Rs m-2,612-3,655 71.5%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Nov 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - NOVARTIS COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS